Pacira BioSciences vs Supernus Pharmaceuticals
Pacira BioSciences reported revenue of $726 million in fiscal 2025, about the same as Supernus Pharmaceuticals' $719 million in fiscal 2025. Pacira BioSciences' revenue grew 3.6% in its latest year, and Supernus Pharmaceuticals' grew 8.6%. Pacira BioSciences had an operating margin of 2.6%, against -8.7% at Supernus Pharmaceuticals. Free cash flow was $137 million at Pacira BioSciences and $46 million at Supernus Pharmaceuticals.
Side by side
| Pacira BioSciences | Supernus Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $726M | $719M |
| Revenue growth | 3.6% | 8.6% |
| Revenue growth a year, last 5 years | 11.1% | 6.7% |
| Gross margin | 79.4% | 89.6% |
| Operating margin | 2.6% | −8.7% |
| Net margin | 1.0% | −5.4% |
| Free cash flow | $137M | $46M |
| Free cash flow margin | 18.8% | 6.4% |
| Return on capital | 1.1% | −7.4% |
| Net debt to EBITDA | 1.2x | −10.5x |
| Dividends and buybacks | $148M | $0M |
| Change in diluted share count | −2.6% | 0.9% |
| Last close | $36.43 | $26.16 |
| P/E at the last close | 39.2× | — |
| Insider trades, last 12 months | sold $2.5 million | sold $10.3 million |
| Piotroski F-score | 9 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Pacira BioSciencesSupernus Pharmaceuticals
Operating margin
Percent of revenue
Pacira BioSciencesSupernus Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Pacira BioSciencesSupernus Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Pacira BioSciences and Supernus Pharmaceuticals pages.